N-[1-(3-benzyl-4-oxoquinazolin-2-yl)propyl]-4-bromo-N-[2-(dimethylamino)ethyl]benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[1-(3-benzyl-4-oxoquinazolin-2-yl)propyl]-4-bromo-N-[2-(dimethylamino)ethyl]benzamide
• 化学式: C₂₉H₃₁BrN₄O₂
• 分子量: 547.5
• InChiKey: VLAOTLYMJVMBKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  56.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Methods and compositions utilizing quinazolinones
  申请人：Finer Jeffrey T.

  公开号：US20080182864A1

  公开（公告）日：2008-07-31

  Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.

  公开了式（a、b、c和d）的喹唑啉酮。它们可用于治疗与KSP肌动蛋白活性相关的细胞增殖性疾病和疾病。
• Methods and Compositions Utilizing Quinazolinones
  申请人：Finer Jeffrey T.

  公开号：US20100063073A1

  公开（公告）日：2010-03-11

  Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.

  公开了式子1a、1b、1c和1d的喹唑啉酮。它们可用于治疗与KSP肌动蛋白活性有关的细胞增殖性疾病和紊乱。
• METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES
  申请人：Finer Jeffrey T.

  公开号：US20100210670A1

  公开（公告）日：2010-08-19

  Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.

  公开了化学式为(a、b、c和d)的喹嗪酮类化合物。它们可用于治疗与KSP肌动蛋白活性相关的细胞增殖性疾病和疾病。
• METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES
  申请人：Finer Jeffrey T.

  公开号：US20130053408A1

  公开（公告）日：2013-02-28

  Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.

  公开了化学式为1a、1b、1c和1d的喹唑啉酮。它们可用于治疗与KSP动力蛋白活性相关的细胞增殖性疾病和疾病。
• Methods for Diagnosis and Treatment of Cancer
  申请人：Bamdad Cynthia C.

  公开号：US20080064680A1

  公开（公告）日：2008-03-13

  The present application discloses methods of detecting and treating cancer which express MUC1 aberrantly.